TC
LGND icon

TFS Capital’s Ligand Pharmaceuticals LGND Stock Holding History

TFS Capital’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-3,852
Closed -$257K – 1087
2016
Q1 		$257K Buy
+3,852
New +$234K 0.04% 693
2015
Q1 		– Sell
-20,727
Closed -$688K – 1042
2014
Q4 		$688K Buy
+20,727
New +$674K 0.07% 483
2014
Q2 		– Sell
-87,163
Closed -$3.66M – 1247
2014
Q1 		$3.66M Buy
+87,163
New +$3.63M 0.24% 103
2013
Q4 		– Sell
-80,249
Closed -$2.17M – 1552
2013
Q3 		$2.17M Buy
80,249
+41,290
+106% +$1.16M 0.1% 298
2013
Q2 		$909K Buy
+38,959
New +$701K 0.04% 637

Other funds holding LGND

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

TFS Capital's LGND Position: Q2 2016 in Review

TFS Capital sold out of Ligand Pharmaceuticals (LGND) in Q2 2016, closing a stake of 3,852 shares — an estimated $257K sold.

TFS Capital first reported a position in LGND in Q2 2013 and held it in 5 quarters. The position peaked at $3.66M in Q1 2014. 265 funds tracked by Wall St. Rank hold LGND as of Q2 2016.

  • TFS Capital reported no remaining Ligand Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • TFS Capital sold 3,852 Ligand Pharmaceuticals shares in Q2 2016, an estimated $257K.
  • TFS Capital first reported a position in Ligand Pharmaceuticals in Q2 2013 and held it in 5 quarters.
  • TFS Capital's Ligand Pharmaceuticals position peaked at $3.66M in Q1 2014.
  • 265 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2016.

Based on TFS Capital's 13F filing for Q2 2016, filed 11 Aug 2016.